Professor Southey, PhD, Grad Dip Law, FHGSA, FFSc (RCPA), has a track record in both molecular diagnostic pathology and molecular genetic research. Her research programs are focused on characterizing the genetic and epigenetic factors responsible for cancer predisposition and progression, including familial aggregation of cancers.
She leads a large active team of researchers, and in parallel, has numerous national and international productive collaborations. Significant focus is placed on the common cancers (breast, colorectal and prostate cancer) utilizing PEDIGREE's mature population-based studies and the application of new genetic technologies. She leads well advanced studies using highly selected multiple-case families that are applying massively parallel sequencing to identify new “high risk” breast and prostate cancer susceptibility genes, has recently led the formation of an international consortium COMPLEXO that aims to pool data to expedite discoveries in this area and has worked to define modes of translation of new genetic information into clinical practice. Her team has substantial activities based on Epigenome-Wide Association Studies (EWASs) utilizing the resources of the Melbourne Collaborative Cohort Study that are working to identify epigenetic risk factors for cancer. These initiatives are working towards improving the healthcare outcomes for individuals at high risk of cancer and providing the foundation for the emerging "Precision Public Health" era.
Find out more about Melissa Southey's experience
Melissa Southey's highlights
FEATURED Journal article
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
Read moreMelissa Southey's selected work
Projects
Displaying the 88 most recent projects by Melissa Southey.
Project Types
56
Research Grant
32
Research Contracts
Scholarly Works
Displaying the 572 most recent scholarly works by Melissa Southey.